VanEck Pharmaceutical ETF (PPH)
| Assets | $1.06B |
| Expense Ratio | 0.36% |
| PE Ratio | 27.56 |
| Forward PE | 15.70 |
| Shares Out | 9.69M |
| Dividend | $2.14 (1.88%) |
| Ex-Dividend Date | Oct 1, 2026 |
| Payout Frequency | Quarterly |
| Payout Ratio | 50.72% |
| Volume | 435,501 |
| Open | 114.14 |
| Previous Close | 112.13 |
| Day's Range | 114.04 - 115.85 |
| 52-Week Low | 90.60 |
| 52-Week High | 118.00 |
| Beta | 0.45 |
| Holdings | 26 |
| Inception Date | Feb 1, 2000 |
About PPH
Fund Home PageThe VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is issued by VanEck.
Top 10 Holdings
71.86% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 20.91% |
| Merck & Co., Inc. | MRK | 13.05% |
| Novo Nordisk A/S | NVO | 5.64% |
| Pfizer Inc. | PFE | 5.15% |
| Teva Pharmaceutical Industries Limited | TEVA | 4.96% |
| McKesson Corporation | MCK | 4.89% |
| Cencora, Inc. | COR | 4.63% |
| Bristol-Myers Squibb Company | BMY | 4.43% |
| GSK plc | GSK | 4.31% |
| Haleon plc | HLN | 3.88% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Oct 1, 2026 | $0.360 | Oct 6, 2026 |
| Jul 1, 2026 | $0.6248 | Jul 7, 2026 |
| Apr 1, 2026 | $0.8441 | Apr 7, 2026 |
| Dec 29, 2025 | $0.3106 | Dec 31, 2025 |
| Oct 1, 2025 | $0.3931 | Oct 6, 2025 |
| Jul 1, 2025 | $0.6069 | Jul 7, 2025 |
Performance
PPH had a total return of 26.77% in the past year, including dividends. Since the fund's inception, the average annual return has been 10.44%.
News
US FDA to review AI-based tool to predict drug-related liver damage
The U.S. FDA's Center for Drug Evaluation and Research said on Wednesday it has accepted a letter of intent for an artificial intelligence-based drug development tool designed to help predict drug-i...
US FDA to monitor clinical trial data in real time in pilot program aimed at speeding approvals
The U.S. Food and Drug Administration launched a pilot program on Monday aimed at allowing the agency to monitor clinical trial data in real time, a step the agency said could cut years from drug ap...
Could pressure to make money faster kill the next lifesaving pill?
When activist investors take a stake in a pharmaceutical company, markets often cheer. The expectation is leaner operations, sharper strategy and higher stock prices.
Britain agrees full text of US-UK pharmaceutical trade deal
Britain said on Thursday it had agreed the full text of a U.S.-UK pharmaceutical partnership, setting out terms under which British-made medicines would enter the United States tariff-free.
Pharma Offers Defensive Plays in an Uncertain Market. Charts Say Buy These 2 Stocks.
Technical indicators for Pfizer and GSK have turned bullish.
Britain will spend more on new medicines in exchange for avoiding tariffs on U.K. pharmaceutical exports to the U.S.
The move marks a victory for the Trump administration's campaign to get other countries to pay more for drugs.
Ozempic—and 14 other popular prescription drugs—will cost less for Medicare after the U.S. government negotiated lower prices
The price cuts will save Medicare billions of dollars in prescription-drug spending.
Final Trade: JCI, PPH, TOL, IBM
The final trades of the day with the Fast Money traders.
Drug Tariffs Are a Sideshow. Trump's Next Move Could Hit Pharma Harder.
What unnerves investors is a lack of clarity on drug pricing.
Big Pharma Unfazed by Trump Tariffs, But Small Biotechs Face Vulnerability
Drugmakers have been bracing for levies and sought to get ahead of them with pledges to invest billions more on domestic manufacturing.
Trump announces 100% tariffs on pharmaceutical drugs, beginning October 1
President Donald Trump said Thursday that he will put import taxes of 100% on pharmaceutical drugs, 50% on kitchen cabinets and bathroom vanities, 30% on upholstered furniture and 25% on heavy trucks ...
Pharma stocks gain, as Trump's tariff move actually could be a win for the sector
Pharmaceutical stocks mostly gained Friday, as traders appeared to shrug off or even cheer President Donald Trump's rollout of a new tariff plan for drugmakers.
Final Trade: MSTR, PPH, TLT, MCD
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Pharma Is Out of Favor. 5 Drug Stocks With Room to Grow.
Despite Eli Lilly's monster 66.8% gain on the year because of weight-loss drugs, the S&P 500 Pharmaceuticals index is down 2.3%.
Biotech Stocks Are Rallying, but the Outlook Isn't Good
The XBI has been climbing this month. On Tuesday it jumped 5.4% to close at $70.91.
3 ETFs in Focus as Race for Vaccine Intensifies
Several companies sit at the forefront of developing a coronavirus vaccine. Gain exposure to each using the following three ETFs.
Best Performing Pharmaceutical ETFs for Q3 2020
The best pharmaceutical ETFs for Q3 2020 are KURE, XPH, and PPH.